Cargando…
COVID-19 Vaccine Effectiveness in Oncology Patients
Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. However, immunocompromised patients we...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214963/ https://www.ncbi.nlm.nih.gov/pubmed/35755900 http://dx.doi.org/10.6004/jadpro.2022.13.4.6 |
_version_ | 1784731112476508160 |
---|---|
author | LA Costa, Rachel |
author_facet | LA Costa, Rachel |
author_sort | LA Costa, Rachel |
collection | PubMed |
description | Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. However, immunocompromised patients were not included in the initial COVID-19 vaccine trials. Will patients with cancer mount an adequate serologic response to vaccination to be protected from COVID-19 infection? Overall, oncology patients had diminished antibody response to the COVID-19 vaccines compared with healthy patients. The patients with the lowest seroconversion rates were those who received anti-CD20 monoclonal antibody therapy, Bruton tyrosine kinase inhibitor therapy, stem cell transplantation, and chimeric antigen receptor T-cell therapy. Although the response may not be robust, expert organizations strongly recommend that oncology patients should pursue COVID-19 vaccination and booster to ensure some degree of protection from infection. Immunocompromised patients should continue to practice mask wearing, social distancing, and proper hand hygiene to minimize the risk of contracting COVID-19. |
format | Online Article Text |
id | pubmed-9214963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Harborside Press LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-92149632022-06-23 COVID-19 Vaccine Effectiveness in Oncology Patients LA Costa, Rachel J Adv Pract Oncol Practice Matters Oncology patients are at greater risk of morbidity and mortality from coronavirus disease 2019 (COVID-19) infection than the general population. Patients with malignancies were prioritized in vaccine distribution to confer protection to a vulnerable population. However, immunocompromised patients were not included in the initial COVID-19 vaccine trials. Will patients with cancer mount an adequate serologic response to vaccination to be protected from COVID-19 infection? Overall, oncology patients had diminished antibody response to the COVID-19 vaccines compared with healthy patients. The patients with the lowest seroconversion rates were those who received anti-CD20 monoclonal antibody therapy, Bruton tyrosine kinase inhibitor therapy, stem cell transplantation, and chimeric antigen receptor T-cell therapy. Although the response may not be robust, expert organizations strongly recommend that oncology patients should pursue COVID-19 vaccination and booster to ensure some degree of protection from infection. Immunocompromised patients should continue to practice mask wearing, social distancing, and proper hand hygiene to minimize the risk of contracting COVID-19. Harborside Press LLC 2022-05 2022-06-21 /pmc/articles/PMC9214963/ /pubmed/35755900 http://dx.doi.org/10.6004/jadpro.2022.13.4.6 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Practice Matters LA Costa, Rachel COVID-19 Vaccine Effectiveness in Oncology Patients |
title | COVID-19 Vaccine Effectiveness in Oncology Patients |
title_full | COVID-19 Vaccine Effectiveness in Oncology Patients |
title_fullStr | COVID-19 Vaccine Effectiveness in Oncology Patients |
title_full_unstemmed | COVID-19 Vaccine Effectiveness in Oncology Patients |
title_short | COVID-19 Vaccine Effectiveness in Oncology Patients |
title_sort | covid-19 vaccine effectiveness in oncology patients |
topic | Practice Matters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214963/ https://www.ncbi.nlm.nih.gov/pubmed/35755900 http://dx.doi.org/10.6004/jadpro.2022.13.4.6 |
work_keys_str_mv | AT lacostarachel covid19vaccineeffectivenessinoncologypatients |